Abstract PS2-03: Comparison of pathologist reads of sp142 and sp263 with quantitative measurement of protein and mRNA in triple negative breast cancer
Swati Gupta, David L. Rimm(Yale University), Jodi Weidler, Aileen I. Fernandez(Yale University), Vesal Yaghoobi(Yale University), Leena McCann, Michael Bates, Emily Reisenbichler(Saint Louis University)
Cited by 1
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753